Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24956358 | 0.83 | NPC1 (0.56) | ABL1TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL24960108 | 0.81 | ABL1 (0.48) | ABL1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL24956359 | 0.81 | NPC1 (0.52) | ABL1TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL24958859 | 0.80 | GAA (0.49) | ABL1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL22468535 | 0.78 | ABL1 (0.49) | ABL1TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL24960094 | 0.77 | NPC1 (0.48) | ABL1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL24956354 | 0.77 | SMYD3 (0.51) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5494574 | 0.77 | ABL1 (0.48) | ABL1NPC1RAB9A | |
| SCHEMBL22449346 | 0.76 | LMNA (0.63) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL29952772 | 0.75 | ABL1 (0.47) | ABL1TAS1R3TAS1R1TAS1R2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | ABL1 4100/4885TAS1R3 156/4885TAS1R1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.